sur JP Jenkins Ltd (isin : GB00BPLKLR77)
E-therapeutics Announces FY2023/24 Results and Pipeline Progress
London, UK, 6 June 2024 - e-therapeutics plc has released its audited financial results for the year ending 31 January 2024 and provided an update on its pipeline.
The company showed significant progress with positive preclinical proof-of-concept data for four GalOmic™ RNAi assets. CEO Ali Mortazavi highlighted continued advancements, including ETX-258 studies in heart failure and a new MASH program, ETX-394. These efforts validate their AI-enhanced R&D approach.
Key progress includes IND-enabling studies for ETX-312 targeting MASH, and advanced plans for ETX-258 and ETX-394. Operationally, the company expanded HepNet™ data, leveraged proprietary data, and made strategic hires.
e-therapeutics also raised £28.9 million in April 2024 and appointed Lord David Prior as Chair in May 2024. Financial highlights show a cash balance of £20.7 million, revenues of £0.3 million, and increased R&D spend leading to a loss of £11.2 million for the year.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de JP Jenkins Ltd